Skip to Content

Ephedrine Sulphate Injection

Dosage Form: injection, solution

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Forr IM, IV or SC Use

Rx only


Ephedrine Sulfate Injection, USP is a sterile solutionn of 50 mg ephedrine sulfate in Water for Injection.

Ephedrine ooccurs as fine, white, oodorless crystals or powder and darkens on exposure to light. It is freely soluble in water and sparingly soluble in alcohol.

The chemical name of ephedrine sulfate is (C10H15NO)2•H2SO4 benzenemethanol α-[l - (methylamino) ethyl] - sufate (2:1) (salt). Its molecular weight is 428 .54. The structural formula is:


Ephedrine sulfate is a potent sympathomimetic that stimulates both α and β receptors and has clinical uses related to both actions. Its peripheral actions, which it owes in part to the release of norepinephrine, simulate responses that are obtained when adrenegenic nerves are stimulated. These include an increase in blood pressure, stimulation of heart muscle, constriction of arterioles, relaxation of the smooth muscle of the bronchi and gastrointestinal tract, and dilation of the pupils. In the bladder, relaxation of the detrusor muscle is not prominent, but the tone of the trigone and vesicle sphincter is increased.

Ephedrine sulfate also has a potent effect on the CNS. It stimulates the cerebral cortex and sub-cortical centers, which accounts for its use in narcolepsy.

The cardiovascular responses reported in man include moderate tachycardia, unchanged or augmened stroke volume, enhanced cardiac output, variable alterations in peripheral resistance and usually a rise in blood pressure. The action of ephedrine is more prominent on the heart than on the blood vessels. Ephedrine sulfate increases the flow of coronary, cerebral and muscle blood.

In patients with myasthenia gravis, administration of Ephedrine Sulfate Injection, USP produces a real but modest increase in motor power. The exact mechanism by which ephedrine sulfate affects skeletal muscle contractions is unknown.


Ephedrine Sulfate Injectionn, USP is indicated in the treatment of allergic disorders, such as bronchial asthma The drug has long been used as a pressor agent, particularly during spinal anesthesia when hypotensionn frequently ooccurs. In Stokes-Adams syndromeme with complete heart block, ephedrine has a value similar to that of epinephrine. It is indicated as a central nervous system stimulant in narcolepsy and depressive states. It is also used in myasthenia gravis.


Allergic reactions to ephedrine sulfate are rare. The hypersensitivity, if known, is a specific contraindication. Patients hypersensitive to other sympathomimetics may also be hypersensitive to ephedrine sulfate.


GENERAL - Special care should be used when administering Ephedrine Sulfate Injection, USP to patients with heart disease, angina pectoris, diabetes, hyperthyroidism, prostatic hypertrophy or hypertension and to patients receiving digitalis. Prolonged use may produce a syndrome resembling an anxiety state. Tolerance to ephedrine sulfate may develop, but temporary discontinuance to the drug restores its original effectiveness.

DRUG INTERACTIONS - Concurrent use of ephedrine sulfate with general anesthetics, especially cyclopropane or halogenated hydrocarbons or digitalis glycosides may cause cardiac arrhythmias, since these medications may sensitize the myocardium to the effects of ephedrine sulfate.

Therapeutic doses of ephedrine sulfate can inhibit the hypotensive effect of guanethidine, bethanidine, and debrisoquin by displacing the adrenergic blockers from their site of action in the sympathetic neurons. The effect in man is seen as a relative or a complete blockade of the antihypertensive drug by a sudden rise in blood pressure. Concomitant use of Ephedrine Sulfate Injection, USP and oxytocics may cause severe hypotension.

Monoamine oxidase inhibitors may potentiate the pressor effect of ephedrine sulfate, possibly resulting in a hypertensive crisis. Ephedrine Sulfate Injection, USP should not be administered during or within 14 days following the administration of MAO inhibitors.

PREGNANCY CATEGORY C - Animal reproduction studies have not been conducted with Ephedrine Sulfate Injection, USP. Also, it is not known whether the drug can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Ephedrine Sulfate Injection, USP should be given to a pregnant woman only if clearly indicated.

It is not known what effect Ephedrine Sulfate Injection, USP may have on the newborn or on the child's later growth and development when the drug is administered to the mother just before or during labor.

NURSING MOTHERS - Ephedrine sulfate is excreted in breast milk. Use by nursing mothers is not recommended because of the higher than usual risks for infants.

Adverse Reactions

With large doses of ephedrine sulfate most patients will experience nervousness, insomnia, vertigo, headache, tachycardia, palpitation and sweating. Some patients have nausea, vomiting and anorexia. Vesical sphincter spasm may occur and result in difficult and painful urination. Urinary retention may develop in males with prostatism.

Primordial pain and cardiac arrhythmias may occur following administration of Ephedrine Sulfate Injection, USP


Prolonged abuse of Ephedrine Sulfate Injection, USP can lead to symptoms of paranoid schizophrenia. When this occurs, patients exhibit such physical signs as tachycardia, poor nutrition and hygiene, fever, cold sweat and dilated pupils.

Some measure of tolerance may develop with prolonged or excessive use but addiction does not occur. Temporary cessation of medication and subsequent readministration restores its effectiveness.


SYMPTOMS - The principal manifestation of ephedrine sulfate poisoning is convulsions. In acute poisoning the following signs and symptoms may occur: nausea, vomiting, chills, cyanosis, irritability, nervousness, fever, suicidal behavior, tachycardia, dilated pupils, blurred vision, opisthotonos, spasms, convulsions, pulmonary edema, gasping respirations, coma and respiratory failure. Initially, the patient may have hypertension, followed later by hypotension accompanied by anuria.

TREATMENT - If respirations are shallow or cyanosis is present, artificial respiration should be administered. Vasopressors are contraindicated. In cardiovascular collapse blood pressure should be maintained.

ANTIDOTE - For hypertension, 5 mg phentolamine mesylate diluted in saline may be administered slowly intravenously, or 100 mg may be given orally. Convulsions may be controlled by diazepam or paraldehyde. Cool applications and dexamethasone 1 mg/kg, administered slowly intravenously, may control pyrexia.


ADULTS - T he usual parenteral dose is 25 to 50 mg given subcutaneously or intramuscularly. Intravenously, 5 to 25 mg may be administered slowly, repeated in 5 to 10 minutes, if necessary.

CHILDREN - The usual subcutaneous or intramuscular dose is 0.5 mg/kg of body weight or 16 .7 mg/square meter of body surface every 4 to 6 hours.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.


Ephedrine Sulfate Injection USP, 50 mg/mL

1 mL vial in packs of 10, NDC 14789-014-01

STORAGE: Store at 20 ° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light.

Principal Display Panel - Carton Label


10 x 2 mL Vials NDC 14789-014-01

Ephedrine Sulfate
Injection, USP

50 mg/mL

1 mL fill in a 2 mL Vial

Single Dose Vial

Preservative Free

For subcutaneous,
intramuscular or
intravenous use.

Rx only

ephedrine sulfate injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:14789-014
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Ephedrine Sulfate (Ephedrine) Ephedrine Sulfate 50 mg  in 1 mL
Inactive Ingredients
Ingredient Name Strength
# Item Code Package Description
1 NDC:14789-014-01 10 VIAL, SINGLE-DOSE in 1 CARTON
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
unapproved drug other 06/08/2015
Labeler - Nexus Pharmaceuticals Inc (620714787)
Revised: 06/2014
Nexus Pharmaceuticals Inc